Диссертация (1141261), страница 20
Текст из файла (страница 20)
Kwiatkowski, S. Mikulich-Gilbertson et al. // Journal ofAcquired Immune Deficiency Syndromes. - 2004. - № 35. - P. 82–88.80. Briggs, A. Decision modelling for health economic evaluation / A. Briggs, K.Claxton, M. Sculpher. - New York, USA: Oxford University Press. - 2011. - 237 p.81. Cambiano, V. Modelling the potential population impact and cost-effectiveness ofself-testing for HIV: evaluation of data requirements / V. Cambiano, S. Mavedzenge,A. Philips // AIDS and behavior. - 2014.
- Vol. 18, Suppl. 4. - P. 450-458.82. Canadian Coordinating Office for Health Technology Assessment Office.Guidelines for economic evaluation of pharmaceuticals: Canada / CanadianCoordinating Office for Health Technology Assessment Office. - 1997.[Электронныйресурс].Режимдоступа:https://www.cadth.ca/media/pdf/peg_e.pdf. (Дата обращения: 07.09.2014).83. Cohen, C. STaR Study : Single-Tablet Regimen Rilpivirine / Emtricitabine /Tenofovir DF Has Non-Inferior Efficacy Compared to Efavirenz / Emtricitabine /Tenofovir DF and Improves Patient Reported Outcome / C.
Cohen. - 2013.[Электронныйресурс].Режимдоступа:https://crine.org/wp-content/blogs.dir/28/files/2013/11/Cohen-STaR-IAS-2013.pdf (Дата обращения:12.10.2014).84. Cohen, C. Week 48 results from a randomized clinical trial of rilpivirine /emtricitabine / tenofovir disoproxil fumarate vs .
efavirenz / emtricitabine / tenofovirdisoproxil fumarate in treatment-naive HIV-1-infected adults / C. Cohen, D. Wohl,J. R. Arribas et al. // AIDS. - 2014. - № 28. - P. 989–997.85. Cohen, M. Prevention of HIV-1 infection with earlyantiretroviral therapy / M.Cohen // The New England journal of medicine.
- 2011. – Vol. 365, № 6. – P. 493–505.13886. Crowell, T. Elite Controllers are Hospitalized More Often than Persons withMedically Controlled HIV / T. Crowell, K. Gebo, J. Blankson et al. // Journal ofInfectious Diseases Advance Access. - 2014. [Электронный ресурс]. Режимдоступа: http://jid.oxfordjournals.org. (Дата обращения: 17.08.2015).87. Eddy, D. Model Transparency and Validation : A Report of the ISPOR-SMDMModeling Good Research Practices Task Force-7 / D. Eddy, W. Hollingworth, J.Caro et al. // Value in health.
- 2012. - №15. - P. 843-850.88. Floor, E. Modelling the Impact of HIV/AIDS: A Literature Review Centre of PolicyStudies / E. Floor, M. Building, W. Road. - 2013. [Электронный ресурс]. Режимдоступа: http//www.monash.edu.au/policy. (Дата обращения: 27.10.2014).89. Geldsetzer, P. Benefits and Costs of the HIV / AIDS Targets for the Post-2015Development Agenda Post-2015 Consensus / P.
Geldsetzer, D. E. Bloom, S. Humairet al. – Copenhagen: «Copenhagen Consensus Center», 2015. – 21 p.90. Guyot, P. Enhanced secondary analysis of survival data: reconstructing the data frompublished Kaplan-Meier survival curves / P. Guyot, A. Ades, M. Ouwens et al. //BMC Medical Research Methodology. - 2012. - Vol. 12, № 1. - P.
9.91. Hasse, B. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study/ B. Hasse, B. Ledergerber, H. Furrer et al. // Clinical infectious diseases : an officialpublication of the Infectious Diseases Society of America. - 2011. – Vol. 53, № 11.- P. 1130–1139.92. Hoyle, M. Improved curve fits to summary survival data: application to economicevaluation of health technologies / M. Hoyle, W. Henley // BMC Medical ResearchMethodology. - 2011. - Vol.
11, № 1. - P. 139.93. ISPOR. Затраты, качество и результаты в здравоохранении. Книга терминовISPOR. Перевод с англ. / ISPOR. - М.: НЬЮДИАМЕД, 2009. - 468 с.94. Krentz, H.B. Pill burden in HIV infection: 20 years of experience / H.B. Krentz, I.Cosman, L. Lee et al. // Antiviral therapy. - 2012. – Vol. 17, № 5. - P. 833–840.95. Kularatna, S. Study protocol: Comparison of inconsistency between time trade offand discrete choice experiments in EQ-5D-3 L health state valuations / S. Kularatna,J. Byrnes, P. A. Scuffham // JHEOR. - 2014. - Vol.
1, № 2. - P. 87-95.13996. Long, E. Effectiveness and cost-effectiveness of strategies to expand antiretroviraltherapy in St. Petersburg, Russia / E. Long, M. Brandeau, C. Galvin et al. // AIDS. 2006. – Vol. 20, № 17. - P. 2207–2215.97. Maitland, D. Switching from twice-daily abacavir and lamivudine to the once-dailyfixed-dose combination tablet of abacavir and lamivudine improves patientadherence and satisfaction with therapy / D.
Maitland, A. Jacksom, J. Osorio et al.// HIV medicine. - 2008. – Vol. 9, № 8. - P. 667–672.98. Manuskopf, J. Prevalence-based economic evaluation / J. Manuskopf // Value inHealth. - 1998. - Vol. 1, № 4. - 251-259.99. Minacori, R. How to model survival in cost-effectiveness analysis? Differencesbetween Markov and Partitioned Survival Analysis models / R. Minacori, J.Bonastre, B. Lueza // ISPOR 18th Annual European Congress. - 2015.[Электронный ресурс]. Режим доступа: http://www.ispor.org. (Дата обращения:15.10.2016).100.Nakagawa, F. Life expectancy living with HIV: recent estimates and futureimplications / F. Nakagawa, M.
May, A. Philips // Current opinion in infectiousdiseases. - 2013. - Vol.26. - P. 17-25.101.Palella, F.J. Simplification to rilpivirine / emtricitabine / tenofovir disoproxilfumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in arandomized trial of HIV-1 RNA-suppressed participants / F.J. Pallela, M. Fisher, P.Tebas et al. // AIDS. - 2014. - № 28. - P. 335–344.102.Patel, P.
Estimating per-act HIV transmission risk: a systematic review / P.Patel, C. Borkowf, J. Brooks et al. // AIDS. - 2014. - №28. - P. 1509-1519.103.Pharmaceutical Management Agency. Prescription for pharmacoeconomicanalysis. Methods for cost-utility analysis / Pharmaceutical Management Agency. 2015. [Электронный ресурс]. Режим доступа: http: www.pharmac.health.nz.(Дата обращения: 07.04.2015).104.Ramsey, S.
Cost-effectiveness analysis alongside clinical trials II: An ISPORgood research practices task force report / S. Ramsey, R. Willke, H. Glick et al. //Value in Health . - 2015 - №18. - P. 161-172.140105.Stover, J. Updates to the Spectrum/Estimation and Projection Package (EPP)model to estimate HIV trends for adults and children (2012) / J. Stover, T.
Brown,M. Marston // Sex Trans Infect. - 2012. - № 88. - P. 11–16.106.Stover, J. The impact and cost of the 2013 WHO recommendations oneligibility for antiretroviral therapy / J. Stover, C. Gopalappa, M. Mahy et al. //AIDS. - 2014. - № 28. - P. 225-230.107.Sonnenberg, F. Markov Models in Medical Decision Making: A PracticalGuide / F. Sonnenberg, R.
Beck // Medical Decision Making. - 1993. - Vol. 13, №4. - P.322-338.108.Sullivan, S. Budget Impact Analysis — Principles of Good Practice: Reportof the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force / S.Sullivan, J. Mauskopf, F. Augusovski et al. // Value in Health. - 2014. - №17.
- P.5-14.109.The DHHS Panel on Antiretroviral. Guidelines for Adults Guidelines for theUse of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents / The DHHSPanel on Antiretroviral. - 2016.[Электронный ресурс]. Режим доступа:https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.(Датаобращения: 15.02.2017).110.UNAIDS. How aids changed everything — mdg6: 15 years, 15 lessons ofhope from the aids response / UNAIDS. - 2015. [Электронный ресурс].
Режимдоступа:http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf. (Датаобращения: 29.08.2016).111.UNAIDS. Invest in HIV prevention / UNAIDS. - 2015. [Электронныйресурс].Режимдоступа:http://www.unaids.org/en/resources/documents/2015/JC2791_invest-in-HIVprevention. (Дата обращения: 05.01.2016).112.Ven, P. A Comparative Demographic and Sexual Profile of OlderHomosexually Active Men / P. Ven, P.
Rodden, J. Crawford et al. // The Journal ofSex Research. - 1997. – Vol. 34, № 4. - P. 349–360.141113.Vickerman, O. The cost-effectiveness of expanding harm reduction activitiesfor injecting drug users in Odessa / O. Vickerman, P. Kumaranayake, L. Balakireva.et al. // Sex Transm Dis. - 2006. - № 33. - P. 89–102.114.Wang, H. Estimates of global, regional, and national incidence, prevalence,and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015 / H.Wang, T.
Wolock, A. Carter et al. // The lancet. HIV. - 2016. – Vol. 3, № 8. - P. 361387.115.Whiteman, M.K. Determinants of contraceptive choice among women withHIV / M.K. Whiteman, D. Kissin, A. Samarina et al. // AIDS. - 2009. - № 23. - P.47-54.116.Weinstein, M. Principles of good practice for decision analytic modeling inhealth-care evaluation: report of the ISPOR Task Force on Good Research PracticesModeling Studies / M.
Weinstein, B. O'Brien, J. Hornberger et al. // Value in Health.- 2003. - Vol. 6, № 1. - P. 9-17.117.Wikimedia Foundation. Цепь Маркова / Wikimedia Foundation. – 2017.[Электронныйресурс]Режимдоступа:https://ru.wikipedia.org/wiki/Цепь_Маркова. (дата обращения 25.12.2016).118.Wilkins, E. Single Tablet Regimens - A Survey of Healthcare ProfessionalsViews on Splitting to Multi-Tablet Regimens / E. Wilkins, D. Lindsay, N. BritoAult et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
